Related Experiment Video
Updated: Aug 26, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Watch-and-wait after immunotherapy-containing neoadjuvant treatment in pMMR/MSS locally advanced rectal cancer: a
Zhenkai Luo1, Renshen Xiang2, Ruihuan Shen3
1Department of Endoscopy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Background:
Watch-and-wait (W&W) is an organ-preserving option for rectal cancer patients who achieve clinical complete response (cCR), but post-cCR outcomes after immunotherapy-containing neoadjuvant treatment in proficient mismatch repair (pMMR)/microsatellite stable (MSS) locally advanced rectal cancer (LARC) remain unclear. We evaluated post-cCR oncological and organ-preservation outcomes in this selected population.
Methods:
This multicenter retrospective cohort study included patients with pMMR/MSS LARC who achieved cCR after immunotherapy-containing neoadjuvant treatment at three medical centers and subsequently underwent W&W. Eligible patients had at least 12 months of post-cCR follow-up. Disease progression, survival, and organ-preservation outcomes were evaluated, and survival was estimated using the Kaplan-Meier method.
Results:
Twenty-five patients were included, with a median post-cCR follow-up of 26 months (range, 14-40 months). Three patients (12.0%) developed disease progression, including two with local regrowth and one with lung metastasis. Both local regrowths were treated with R0 salvage surgery. The estimated 2-year disease-free survival was 87.4% (95% CI, 65.7%-95.8%). Twenty-three patients (92.0%) avoided radical surgery, and 22 patients (88.0%) maintained disease-free organ preservation.
Conclusion:
This multicenter study provides preliminary real-world evidence on W&W after cCR in highly selected patients with pMMR/MSS LARC treated with immunotherapy-containing neoadjuvant regimens, but larger prospective comparative studies with longer follow-up are required before its feasibility and oncological safety can be established.
